Gastroenterology or gastrology is the medical specialty concerned with digestive diseases. Traditionally, these are separated by anatomic or functional category. For example, disorders of the esophagus might be listed under "esophagus" and also included in a description of motility disorders (disorders of motor function.) Diseases of the liver fall under the branch of hepatology, which is traditionally classified under the umbrella of gastroenterology.

List of signs and symptoms of gastroenterological diseases:

• constipation
• diarrhea
• vomiting
• nausea
• abdominal pain

List of research fields in Gastroenterology:

• Neurogastroenterology
• Motility

More on [ Gastroenterology ]

Permanent Gastroenterology Jobs

Great Location :: Arizona :: Intelligent Placement Solutions, Inc
Tue, 09 Feb 2010 17:02:22 -0500
An excellent opportunity to join our small 2 person GI practice in sunny Phoenix, AZ/ Rapidly growing area with 3 brand new hospitals. Competitive salary with strong earning potential (550K+), easy
Great Location :: Maryland :: Intelligent Placement Solutions, Inc
Tue, 09 Feb 2010 17:02:22 -0500
Premier single specialty group of Gastroenterologists seeks additional GI for a growing and well-established practice. Physician to practice in new community practice/office location in area with existing
Great Location :: Massachusetts :: Intelligent Placement Solutions, Inc
Tue, 09 Feb 2010 17:02:22 -0500
Need BC candidate with MA license to start in the next 3-4 months. Offering $400K with $100K sign on bonus.We invite team oriented, motivated physicians to a hospital employed position. We offer an

FeedNavigator - Journals - Gastroenterology

Information for Authors and Readers
Clinical Gastroenterology and Hepatology @FeedNavigator Tue, 09 Feb 2010 22:44:45 +0200

Contents
Clinical Gastroenterology and Hepatology @FeedNavigator Tue, 09 Feb 2010 22:44:45 +0200

Editorial Board
Clinical Gastroenterology and Hepatology @FeedNavigator Tue, 09 Feb 2010 22:44:45 +0200

Cover
Clinical Gastroenterology and Hepatology @FeedNavigator Tue, 09 Feb 2010 22:44:45 +0200

Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes?
Clinical Gastroenterology and Hepatology @FeedNavigator Tue, 09 Feb 2010 22:44:45 +0200

Copyright Assignment, Authorship Responsibility, NIH Funding, Financial Disclosure, Institutional Review Board/Animal Care Committee Approval, and Sponsorship
Clinical Gastroenterology and Hepatology @FeedNavigator Tue, 09 Feb 2010 22:44:45 +0200


pubmed: 1542-3565

Low dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease.
Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D Related Articles Low dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010 Feb 4; Authors: Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D BACKGROUND & AIMS:: Infliximab might prevent post-surgical recurrence of Crohn's disease. However, it is unclear whether long term therapy with this drug is necessary and whether alternative strategies could be applied, to minimize potential side effects and reduce the costs of treatment. METHODS:: We performed a prospective cohort study in 12 consecutive patients, treated immediately after surgery with maintenance infliximab (5 mg/Kg), who did not have clinical or endoscopic evidence of disease recurrence after 24 months; they were followed for an additional year. Treatment with infliximab was then discontinued; patients with disease recurrence, based on endoscopy results (Rutgeerts score </=2), were given lower doses of infliximab (starting with 1 mg/Kg) in an attempt to re-establish mucosal integrity. Surrogate markers of disease activity (fecal calprotectin [FC], CRP, and ESR) were assessed after each dose of infliximab. RESULTS:: None of the patients had clinical or endoscopic recurrence of Crohn's disease 3 years after surgery. However, discontinuation of infliximab therapy caused endoscopic recurrence after 4 months in 10/12 patients (83%). All these 10 patients were then treated again with infliximab which, at a dose of 3 mg/Kg every 8-week, restored and mantained mucosal integrity for 1 year. Among the surrogate markers, FC levels correlated with endoscopic scores (Wald test, p < 0.0001). CONCLUSIONS:: Long-term maintenance therapy with infliximab is required to maintain mucosal integrity in patients following surgery for Crohn's disease. However, a dose of 3 mg/Kg (a 40% reduction from the standard dose) was sufficient to avoid disease recurrence, determined by endoscopy, in all patients at one year. FC levels correlate with mucosal status at different infliximab doses. PMID: 20139033 [PubMed - as supplied by publisher]

Clin Gastroenterol Hepatol. 2010 Feb 3; Authors: PMID: 20138248 [PubMed - as supplied by publisher]

Nature Reviews Gastroenterology and Hepatology - Issue - nature.com science feeds

The expanding role of biologic therapy for IBD
Stephen B. HanauerThe topic of biologic therapy for IBD has been selected for this Focus issue of Nature Reviews Gastroenterology & Hepatology because of the important implications it has for disease management. Four biologic agents are currently marketed for the treatment of IBD in the US
IBD: High dietary intake of linoleic acid more than doubles the risk of ulcerative colitis
Natalie J. WoodA high dietary intake of linoleic acid—an essential n-6 polyunsaturated fatty acid found in red meats, polyunsaturated margarines and various cooking oils—more than doubles the risk of developing incident ulcerative colitis, according to the results of a new multicenter European study.Linoleic acid is converted
H. Hepaticus and biliary disease
Rowan HiggsSince the discovery of Helicobacter pylori, the association of other Helicobacter spp. with gastrointestinal disease has been of particular interest to clinicians. New evidence from Toshihide Hamada and colleagues suggests an association between colonization of the hepatobiliary system by H. hepaticus and

Inflammatory Bowel Diseases

Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity
Shih-Kuang S. Hong, Rupesh Chaturvedi, M. Blanca Piazuelo, Lori A. Coburn, Christopher S. Williams, Alberto G. Delgado, Robert A. Casero Jr, David A. Schwartz, Keith T. Wilson Tue, 02 Feb 2010 14:38:00 -0000
Polyamines are important in cell growth and wound repair, but have also been implicated in inflammation-induced carcinogenesis. Polyamine metabolism includes back-conversion of spermine to spermidine by the enzyme spermine oxidase (SMO), which produces hydrogen peroxide that causes oxidative stress. In ulcerative colitis (UC), levels of spermine are decreased compared to spermidine. Therefore, we sought to determine if SMO is involved in UC.Colon biopsies and clinical information from subjects undergoing colonoscopy for evaluation of UC or colorectal cancer screening were utilized from 16 normal controls and 53 UC cases. Histopathologic disease severity was graded and the Mayo Disease Activity Index (DAI) and endoscopy subscore assessed. SMO mRNA expression was measured in frozen biopsies by TaqMan-based real-time polymerase chain reaction (PCR). Formalin-fixed tissues were used for SMO immunohistochemistry.There was a 3.1-fold upregulation of SMO mRNA levels in UC patients compared to controls (P = 0.044), and a 3.7-fold increase in involved left colon versus paired uninvolved right colon (P < 0.001). With worsening histologic injury in UC there was a progressive increase in SMO staining of mononuclear inflammatory cells. There was a similar increase in SMO staining with worsening endoscopic disease severity and strong correlation with the DAI (r = 0.653, P < 0.001). Inflammatory cell SMO staining was increased in involved left colon versus uninvolved right colon.SMO expression is upregulated in UC tissues, deriving from increased levels in mononuclear inflammatory cells. Dysregulated polyamine homeostasis may contribute to chronic UC by altering immune responses and increasing oxidative stress. (Inflamm Bowel Dis 2010;)
Inflammatory bowel diseases and health service: The necessity for a new strategy
A.M. El-Tawil Tue, 02 Feb 2010 14:38:00 -0000
No abstract.
Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score
Jessica J. Lee, Johanna C. Escher, Melissa J. Shuman, Peter W. Forbes, Luçan C. Delemarre, Brian W. Harr, Marjan Kruijer, Marlous Moret, Sophie Allende-Richter, Richard J. Grand Tue, 02 Feb 2010 14:38:00 -0000
This study was designed to elucidate the contribution of parental height to the stature of children with inflammatory bowel disease (IBD), who often exhibit growth impairment. Accordingly, we compared patients' final adult heights and target heights based on measured parental heights and examined predictors of final adult height in pediatric IBD patients.We prospectively analyzed the growth of 295 patients diagnosed between ages 1 and 18 (211 Crohn's disease [CD], 84 ulcerative colitis [UC]) and their family members (283 mothers, 231 fathers, 55 siblings).Twenty-two percent had growth impairment (height for age Z-score <-1.64, equivalent to <5th percentile on growth curve) in more than 1 measurement since diagnosis; most growth-impaired patients had CD (88% CD versus 12% UC). Parents of the growth-impaired group had lower mean height Z-scores compared to parents of nongrowth-impaired patients (-0.67 versus 0.02 for mothers [P < 0.001]; -0.31 versus 0.22 for fathers [P = 0.002]). For 108 patients who reached adult heights and had available parental heights, the growth-impaired group continued to demonstrate lower adult height Z-scores (-1.38 versus 0.07; P < 0.001). Adult heights were within 1 SD of target heights even for the growth-impaired group. Only 11.3% remained persistently growth-impaired in adulthood. Multivariate regression analysis demonstrated lower parental height and minimum patient height Z-score as significant predictors of lower final adult height in IBD.Parental height is a powerful determinant of linear growth even in the presence of chronic inflammation, and should be an integral part of the evaluation of growth in IBD children. (Inflamm Bowel Dis 2010)

Subscribe to Gastroenterology RSS feed